Key result
Haloperidol and subsequent fluoxetine exposure linked to neuroleptic malignant syndrome and fatal serotonin syndrome.
Why the study?
This is the first clinicopathologic case report of a patient who experienced both neuroleptic malignant syndrome and serotonin syndrome, highlighting potential shared pathogenetic mechanisms.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
This first reported clinicopathologic case of a patient experiencing both neuroleptic malignant and serotonin syndromes suggests they may share fundamental pathogenetic mechanisms.
We report the case of a 24-year-old female patient who initially developed a neuroleptic malignant syndrome after haloperidol exposure and experienced 6 years later a serotonin syndrome after repeated fluoxetine exposure. The patient did not respond to symptomatic treatment and died in this latter episode. At necropsy, no gross or microscopic changes were seen with conventional histological stains, and immunohistochemical stains were negative. This is the first clinicopathologic case of a patient who experienced both neuroleptic malignant and serotonin syndromes. We speculate that this case argue in favor that both syndromes share some fundamental pathogenetic mechanisms.
No takes yet. Share an insight, caveat, or question.
Gómez‐Esteban et al. (2009) conducted a case report in Neuroleptic Malignant Syndrome and Serotonin Syndrome (n=1). Haloperidol and fluoxetine was evaluated on Clinical outcome and necropsy findings. A 24-year-old female patient developed neuroleptic malignant syndrome after haloperidol exposure and later died from serotonin syndrome after fluoxetine exposure, with no specific necropsy findings.
Synapse has enriched 10 related papers. Consider them for comparative context: